{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:43:43Z","timestamp":1779889423847,"version":"3.53.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s12185-022-03461-2","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T12:02:27Z","timestamp":1665230547000},"page":"821-827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Biological and clinical significance of epigenetic alterations in B-cell lymphomas"],"prefix":"10.1007","volume":"116","author":[{"given":"Daisuke","family":"Ennishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,8]]},"reference":[{"issue":"20","key":"3461_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201391.","journal-title":"Blood"},{"issue":"2","key":"3461_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/ng.518","volume":"42","author":"RD Morin","year":"2010","unstructured":"Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2):181\u20135.","journal-title":"Nat Genet"},{"issue":"2","key":"3461_CR3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/ng.2856","volume":"46","author":"J Okosun","year":"2014","unstructured":"Okosun J, B\u00f6d\u00f6r C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014;46(2):176\u201381.","journal-title":"Nat Genet"},{"issue":"2","key":"3461_CR4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/ng.3473","volume":"48","author":"J Okosun","year":"2015","unstructured":"Okosun J, Wolfson RL, Wang J, et al. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat Genet. 2015;48(2):183\u20138.","journal-title":"Nat Genet"},{"issue":"9","key":"3461_CR5","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111\u201322.","journal-title":"Lancet Oncol"},{"issue":"12","key":"3461_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1002197","volume":"13","author":"R Kridel","year":"2016","unstructured":"Kridel R, Chan FC, Mottok A, et al. Histological transformation and progression in follicular lymphoma: a clonal evolution study. PLoS Med. 2016;13(12):1\u201325.","journal-title":"PLoS Med"},{"issue":"1","key":"3461_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1182\/blood-2018-07-865428","volume":"133","author":"X Qu","year":"2019","unstructured":"Qu X, Li H, Braziel RM, et al. Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016. Blood. 2019;133(1):81\u201393.","journal-title":"Blood"},{"issue":"6769","key":"3461_CR8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503\u201311.","journal-title":"Nature"},{"issue":"1","key":"3461_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nm0102-68","volume":"8","author":"MA Shipp","year":"2002","unstructured":"Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8(1):68\u201374.","journal-title":"Nat Med"},{"issue":"25","key":"3461_CR10","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937\u201347.","journal-title":"N Engl J Med"},{"issue":"7360","key":"3461_CR11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10351","volume":"476","author":"RD Morin","year":"2011","unstructured":"Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298\u2013303.","journal-title":"Nature"},{"issue":"7","key":"3461_CR12","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1182\/blood-2013-02-483727","volume":"122","author":"RD Morin","year":"2013","unstructured":"Morin RD, Mungall K, Pleasance E, et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013;122(7):1256\u201365.","journal-title":"Blood"},{"issue":"4","key":"3461_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41591-020-0757-z","volume":"26","author":"D Ennishi","year":"2020","unstructured":"Ennishi D, Healy S, Bashashati A, et al. TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Nat Med. 2020;26(4):577\u201388.","journal-title":"Nat Med"},{"issue":"9","key":"3461_CR14","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/ng.892","volume":"43","author":"L Pasqualucci","year":"2011","unstructured":"Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830\u20137.","journal-title":"Nat Genet"},{"issue":"10","key":"3461_CR15","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1073\/pnas.1121343109","volume":"109","author":"JG Lohr","year":"2012","unstructured":"Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012;109(10):3879\u201384.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3461_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","volume":"171","author":"A Reddy","year":"2017","unstructured":"Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481-494.e15.","journal-title":"Cell"},{"issue":"15","key":"3461_CR17","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396\u2013407.","journal-title":"N Engl J Med"},{"issue":"5","key":"3461_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679\u201390.","journal-title":"Nat Med"},{"issue":"10","key":"3461_CR19","doi-asserted-by":"publisher","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","volume":"112","author":"MR Green","year":"2015","unstructured":"Green MR, Kihira S, Liu CL, et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci U S A. 2015;112(10):E1116\u201325.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"3461_CR20","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","volume":"121","author":"MR Green","year":"2013","unstructured":"Green MR, Gentles AJ, Nair RV, et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood. 2013;121(9):1604\u201311.","journal-title":"Blood"},{"issue":"1","key":"3461_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.beha.2017.10.006","volume":"31","author":"T Lackraj","year":"2018","unstructured":"Lackraj T, Goswami R, Kridel R. Pathogenesis of follicular lymphoma. Best Pract Res Clin Haematol. 2018;31(1):2\u201314.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"3461_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","volume":"6","author":"L Pasqualucci","year":"2014","unstructured":"Pasqualucci L, Khiabanian H, Fangazio M, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;6(1):130\u201340.","journal-title":"Cell Rep"},{"issue":"20","key":"3461_CR23","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJM199911113412007","volume":"341","author":"R K\u00fcppers","year":"1999","unstructured":"K\u00fcppers R, Klein U, Hansmann ML, Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med. 1999;341(20):1520\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"3461_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrc1589","volume":"5","author":"R K\u00fcppers","year":"2005","unstructured":"K\u00fcppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5(4):251\u201362.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3461_CR25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1146\/annurev-immunol-020711-075032","volume":"30","author":"GD Victora","year":"2012","unstructured":"Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol. 2012;30(1):429\u201357.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"3461_CR26","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.immuni.2015.11.019","volume":"43","author":"JG Cyster","year":"2015","unstructured":"Cyster JG. Germinal centers: gaining strength from the dark side. Immunity. 2015;43(6):1026\u20138.","journal-title":"Immunity"},{"issue":"1","key":"3461_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/ng.2007.35","volume":"40","author":"L Pasqualucci","year":"2008","unstructured":"Pasqualucci L, Bhagat G, Jankovic M, et al. AID is required for germinal center-derived lymphomagenesis. Nat Genet. 2008;40(1):108\u201312.","journal-title":"Nat Genet"},{"issue":"40","key":"3461_CR28","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1038\/sj.onc.1204640","volume":"20","author":"R K\u00fcppers","year":"2001","unstructured":"K\u00fcppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene. 2001;20(40):5580\u201394.","journal-title":"Oncogene"},{"issue":"5","key":"3461_CR29","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","volume":"23","author":"W B\u00e9guelin","year":"2013","unstructured":"B\u00e9guelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;23(5):677\u201392.","journal-title":"Cancer Cell"},{"issue":"2","key":"3461_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ccell.2016.07.006","volume":"30","author":"W B\u00e9guelin","year":"2016","unstructured":"B\u00e9guelin W, Teater M, Gearhart MD, et al. EZH2 and BCL6 cooperate to assemble CBX8-BCOR complex to repress bivalent promoters, mediate germinal center formation and lymphomagenesis. Cancer Cell. 2016;30(2):197\u2013213.","journal-title":"Cancer Cell"},{"issue":"1","key":"3461_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-01029-x","volume":"8","author":"W B\u00e9guelin","year":"2017","unstructured":"B\u00e9guelin W, Rivas MA, Calvo Fern\u00e1ndez MT, et al. EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop. Nat Commun. 2017;8(1):1\u201316.","journal-title":"Nat Commun"},{"issue":"25","key":"3461_CR32","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1182\/blood-2012-12-473439","volume":"123","author":"T Berg","year":"2014","unstructured":"Berg T, Thoene S, Yap D, et al. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. Blood. 2014;123(25):3914\u201324.","journal-title":"Blood"},{"issue":"5","key":"3461_CR33","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ccell.2020.04.004","volume":"37","author":"W B\u00e9guelin","year":"2020","unstructured":"B\u00e9guelin W, Teater M, Meydan C, et al. Mutant EZH2 induces a pre-malignant lymphoma niche by reprogramming the immune response. Cancer Cell. 2020;37(5):655-673.e11.","journal-title":"Cancer Cell"},{"issue":"10","key":"3461_CR34","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/nm.3943","volume":"21","author":"A Ortega-Molina","year":"2015","unstructured":"Ortega-Molina A, Boss IW, Canela A, et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat Med. 2015;21(10):1199\u2013208.","journal-title":"Nat Med"},{"issue":"10","key":"3461_CR35","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/nm.3940","volume":"21","author":"J Zhang","year":"2015","unstructured":"Zhang J, Dominguez-Sola D, Hussein S, et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat Med. 2015;21(10):1190\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"3461_CR36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41590-018-0273-1","volume":"20","author":"K Hatzi","year":"2019","unstructured":"Hatzi K, Geng H, Doane AS, et al. Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. Nat Immunol. 2019;20(1):86\u201396.","journal-title":"Nat Immunol"},{"issue":"7337","key":"3461_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nature09730","volume":"471","author":"L Pasqualucci","year":"2011","unstructured":"Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471(7337):189\u201395.","journal-title":"Nature"},{"issue":"1","key":"3461_CR38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/2159-8290.CD-16-0975","volume":"7","author":"Y Jiang","year":"2017","unstructured":"Jiang Y, Ortega-Molina A, Geng H, et al. CREBBP inactivation promotes the development of HDAC3-dependent lymphomas. Cancer Discov. 2017;7(1):38\u201353.","journal-title":"Cancer Discov"},{"issue":"3","key":"3461_CR39","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1158\/2159-8290.CD-16-1417","volume":"7","author":"J Zhang","year":"2017","unstructured":"Zhang J, Vlasevska S, Wells VA, et al. The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma. Cancer Discov. 2017;7(3):323\u201337.","journal-title":"Cancer Discov"},{"issue":"3","key":"3461_CR40","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/2159-8290.CD-19-0116","volume":"10","author":"P Mondello","year":"2020","unstructured":"Mondello P, Tadros S, Teater M, et al. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discov. 2020;10(3):440\u201359.","journal-title":"Cancer Discov"},{"issue":"10","key":"3461_CR41","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1038\/bcj.2015.89","volume":"5","author":"MA Lunning","year":"2015","unstructured":"Lunning MA, Green MR. Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas. Blood Cancer J. 2015;5(10):e361.","journal-title":"Blood Cancer J"},{"issue":"3","key":"3461_CR42","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.celrep.2013.06.016","volume":"4","author":"K Hatzi","year":"2013","unstructured":"Hatzi K, Jiang Y, Huang C, et al. A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. Cell Rep. 2013;4(3):578\u201388.","journal-title":"Cell Rep"},{"issue":"4","key":"3461_CR43","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","volume":"9","author":"D Ennishi","year":"2019","unstructured":"Ennishi D, Takata K, B\u00e9guelin W, et al. Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition. Cancer Discov. 2019;9(4):546\u201363.","journal-title":"Cancer Discov"},{"issue":"9","key":"3461_CR44","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/2159-8290.CD-20-0174","volume":"10","author":"D Ennishi","year":"2020","unstructured":"Ennishi D, Hsi ED, Steidl C, Scott DW. Toward a new molecular taxonomy of diffuse large B-cell lymphoma. Cancer Discov. 2020;10(9):1267\u201381.","journal-title":"Cancer Discov"},{"issue":"21","key":"3461_CR45","doi-asserted-by":"publisher","first-page":"5999","DOI":"10.1073\/pnas.1602069113","volume":"113","author":"S Yoshihama","year":"2016","unstructured":"Yoshihama S, Roszik J, Downs I, et al. NLRC5\/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci. 2016;113(21):5999\u20136004.","journal-title":"Proc Natl Acad Sci"},{"issue":"7338","key":"3461_CR46","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nature09754","volume":"471","author":"C Steidl","year":"2011","unstructured":"Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471(7338):377\u201381.","journal-title":"Nature"},{"issue":"10","key":"3461_CR47","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.3324\/haematol.2011.060186","volume":"97","author":"M Schmelz","year":"2012","unstructured":"Schmelz M, Montes-Moreno S, Piris M, Wilkinson ST, Rimsza LM. Lack and\/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphoma. Haematologica. 2012;97(10):1614\u20136.","journal-title":"Haematologica"},{"issue":"12","key":"3461_CR48","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nri3339","volume":"12","author":"KS Kobayashi","year":"2012","unstructured":"Kobayashi KS, Van Den Elsen PJ. NLRC5: A key regulator of MHC class I-dependent immune responses. Nat Rev Immunol. 2012;12(12):813\u201320.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"3461_CR49","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/imm.12136","volume":"140","author":"KA Cycon","year":"2013","unstructured":"Cycon KA, Mulvaney K, Rimsza LM, Persky D, Murphy SP. Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma. Immunology. 2013;140(2):259\u201372.","journal-title":"Immunology"},{"issue":"1","key":"3461_CR50","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.immuni.2020.11.002","volume":"54","author":"D Dersh","year":"2021","unstructured":"Dersh D, Phelan JD, Gumina ME, et al. Genome-wide screens identify lineage- and tumor-specific genes modulating MHC-I- and MHC-II-restricted immunosurveillance of human lymphomas. Immunity. 2021;54(1):116-131.e10.","journal-title":"Immunity"},{"key":"3461_CR51","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.molimm.2020.01.006","volume":"119","author":"Y Otsuka","year":"2020","unstructured":"Otsuka Y, Nishikori M, Arima H, et al. EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas. Mol Immunol. 2020;119:35\u201345.","journal-title":"Mol Immunol"},{"key":"3461_CR52","doi-asserted-by":"crossref","unstructured":"Takata K, Chong LC, Ennishi D, et al. 2022 Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. J Clin Invest. 132(10)","DOI":"10.1172\/JCI145343"},{"issue":"3","key":"3461_CR53","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.18.01583","volume":"37","author":"D Ennishi","year":"2019","unstructured":"Ennishi D, Jiang A, Boyle M, et al. Double-hit gene expression signature defines a distinct subgroup of germinal center b-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(3):190\u2013201.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3461_CR54","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/JCO.18.01314","volume":"37","author":"C Sha","year":"2019","unstructured":"Sha C, Barrans S, Cucco F, et al. Molecular high-grade B-cell lymphoma: Defining a poor-risk group that requires different approaches to therapy. J Clin Oncol. 2019;37(3):202\u201312.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3461_CR55","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/bjh.16159","volume":"188","author":"S Lockmer","year":"2020","unstructured":"Lockmer S, Ren W, Brodtkorb M, et al. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy. Br J Haematol. 2020;188(2):259\u201367.","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"3461_CR56","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2021-144803","volume":"138","author":"LC Adolph","year":"2021","unstructured":"Adolph LC, Fichaux Q, Strobl CD, et al. CHOP but not bendamustine reverses EZH2 Y641 mutation induced MHC-I\/ii loss in human lymphoma models. Blood. 2021;138(Supplement 1):2391\u20132391.","journal-title":"Blood"},{"issue":"5","key":"3461_CR57","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","volume":"19","author":"A Italiano","year":"2018","unstructured":"Italiano A, Soria JC, Toulmonde M, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018;19(5):649\u201359.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3461_CR58","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433\u201342.","journal-title":"Lancet Oncol"},{"issue":"9","key":"3461_CR59","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1111\/cas.15040","volume":"112","author":"K Izutsu","year":"2021","unstructured":"Izutsu K, Ando K, Nishikori M, et al. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan. Cancer Sci. 2021;112(9):3627\u201335.","journal-title":"Cancer Sci"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03461-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03461-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03461-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T11:28:04Z","timestamp":1668770884000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03461-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,8]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3461"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03461-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,8]]},"assertion":[{"value":"2 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DE has received honoraria from Chugai Pharmaceutical, Kyowa Kirin and Eisai, and has received research funding from Chugai Pharmaceutical and Nippon Shinyaku.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}